View Older Stories View More Recent Stories

Mar 11, 2024 07:00AM Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Mar 6, 2024 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 27, 2024 07:05AM Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 26, 2024 07:00AM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 20, 2024 07:00AM Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
Feb 6, 2024 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 26, 2024 07:07AM Apellis Pharmaceuticals (APLS) Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union
Jan 26, 2024 07:06AM Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
Jan 8, 2024 09:03AM Apellis Pharmaceuticals (APLS) Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
Jan 8, 2024 09:00AM Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
Jan 5, 2024 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 2, 2024 07:00AM Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 28, 2023 07:00AM Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
Dec 14, 2023 07:02AM Apellis Pharmaceuticals (APLS) Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the EU
Dec 14, 2023 07:00AM Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
Dec 11, 2023 07:04AM Apellis Pharmaceuticals (APLS) Announces EMPAVELI Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
Dec 11, 2023 07:00AM EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
Dec 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 21, 2023 07:00AM Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
Nov 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2023 01:37PM SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
Nov 1, 2023 07:05AM Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
Oct 25, 2023 07:00AM Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
Oct 20, 2023 08:02AM Apellis Pharmaceuticals (APLS) Announces Publication of 24-Month Results from Phase 3 Studies of SYFOVRE
Oct 20, 2023 08:00AM The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
Oct 17, 2023 07:00AM Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
Oct 17, 2023 07:00AM Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
Oct 5, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2023 07:01AM Apellis Pharmaceuticals (APLS) Reports Prelim Q3 US Sales of SYFOVRE of $74M
Oct 5, 2023 07:00AM Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
Oct 2, 2023 07:00AM Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
Sep 25, 2023 10:44AM ROSEN, A LEADING AND RANKED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
Sep 25, 2023 07:32AM Apellis Pharmaceuticals (APLS) Receives Permanent J-Code (J2781) for SYFOVRE
Sep 25, 2023 07:30AM Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
Sep 14, 2023 05:07PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
Sep 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 5, 2023 07:00AM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 30, 2023 07:00AM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 29, 2023 06:58AM Apellis Pharmaceuticals (APLS) Announces Corporate Restructuring, Will Cut 25% Staff
Aug 29, 2023 06:58AM Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
Aug 26, 2023 10:44AM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
Aug 22, 2023 04:43PM Apellis Pharmaceuticals (APLS) Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE
Aug 22, 2023 04:43PM Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
Aug 16, 2023 08:27PM ROSEN, A LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
Aug 4, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 31, 2023 07:00AM Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
Jul 31, 2023 05:43AM Apellis (APLS) Provides Update on Review of Rare Safety Events with SYFOVRE
Jul 31, 2023 05:42AM Apellis Pharmaceuticals (APLS) Reports SYFOVRE Continued to Demonstrate Increasing Treatment Effects Over 30 Months
Jul 30, 2023 01:00PM SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
Jul 29, 2023 02:52PM Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
View More Recent Stories View Older Stories